Eye Test in First Grade Leads to Diagnosis of Young Girl's Incurable Disease

Three years ago, Isla Edwards, then 7 years old, was living the life of a normal child in Texas. Her mother, Jacquelyn Stockdale, took her for what appeared to be a routine eye exam to investigate her daughter's "fuzzy" vision. With the expectation that Isla might just need glasses, the diagnosis they received instead was beyond their worst nightmares and changed the course of their lives irrevocably.

A Routine Checkup Turns Into a Life-Changing Event

After an eye test that many would consider straightforward, the ophthalmologist immediately sensed something was off. Without wasting any time, he referred Isla and her family to Texas Children's Hospital in Houston.

"To say we were caught off guard would be an understatement. I was expecting to leave with a prescription for eyeglasses, not with my world turned upside down," said a disheartened Stockdale.

Further examinations and genetic testing revealed that Isla had signs of pediatric macular degeneration. The underlying culprit was diagnosed as neuronal ceroid lipofuscinoses, or more specifically, CLN3 juvenile Batten disease. This is an extremely rare, incurable, and fatal illness with no available treatment. This genetic disorder affects the nervous system and causes symptoms like vision loss, seizures, and early-onset dementia.

"I had to digest the fact that Isla would not only lose her vision but also likely suffer from childhood dementia, epilepsy, and a precipitous decline in her mental and physical abilities," Stockdale detailed.

Faced with the harrowing reality that her child's life could be tragically short, stretching only into the late teens or early twenties, the family was emotionally shattered.

"There were no indications that she was anything less than a perfect, joyful little girl. Telling my family the news was one of the hardest things I've ever had to do," said Stockdale.

Read Also: 3-Year-Old Boy Contracts Rare Tick-Borne Disease from Swimming Pool

Protective Silence and an Adaptive Spirit

Due to the severity and emotional complexity of the diagnosis, the family chose not to discuss it with Isla.

"We believe it's not a burden she should have to bear," Stockdale explained.

Meanwhile, Isla has exhibited incredible resilience. Despite losing 90% of her vision over the past two years, she continues to enjoy life, learning to read Braille and walk with a cane. Her spirit remains undiminished as she continues to indulge in her favorite activities like swimming, dancing, and video games.

What has truly been a ray of light in these trying times is a medication called Miglustat. Approved for Gaucher disease and currently under clinical trials for Batten disease, Isla has been on this medication since November 2022. The drug has had a remarkable effect, effectively halting the deterioration of her condition.

Yet this comes at a significant financial cost. The medication costs a staggering $18,000 per month, an amount that the family has turned to crowdfunding to afford. "The expense is overwhelming, but the impact on Isla's life is beyond any monetary value," said Stockdale.

Isla's journey is far from over, but her family finds solace and immense pride in her fortitude. "We want her to know that her condition doesn't make her less than anyone; it makes her even more extraordinary," emphasized Stockdale. While they still face an uncertain future, the Edwards family's tale serves as a testament to the strength of the human spirit and the advances in medicine that offer a glimmer of hope in the darkest of times.

Related Article: A Parent's Guide to Polio Vaccination: Understanding Why It's Essential for Your Child's Well-being